genprowebdirectory
Facebook Linkedin RSS Twitter Youtube
  • GEN Edge
    • Featured News
    • Multimedia
  • News
    • Insights
  • Topics
    • Artificial Intelligence
    • Bioprocessing
    • Cancer
    • Drug Discovery
    • Genome Editing
    • Infectious Diseases
    • OMICs
    • Translational Medicine
  • Magazine
    • Browse Issues
    • Subscribe
  • Multimedia
    • Summits
    • Webinars
    • GEN Live
    • Learning Labs
    • Podcasts
  • Resources
    • eBooks/Perspectives
    • Tutorials
    • Peer-Reviewed Journals
      • GEN Biotechnology
      • Re:Gen Open
    • New Products
    • Conference Calendar
  • Subscribe
    • Get GEN Magazine
    • Get GEN eNewsletters
Search
Facebook Linkedin RSS Twitter Youtube
Sign in
Welcome! Log into your account
Forgot your password? Get help
Privacy Policy
Password recovery
Recover your password
A password will be e-mailed to you.
Genetic Engineering & Biotechnology News GEN – Genetic Engineering and Biotechnology News
Genetic Engineering & Biotechnology News Genetic Engineering & Biotechnology News
  • GEN Edge
    • Featured News
    • Multimedia
  • News
    • Insights
  • Topics
    • Artificial Intelligence
    • Bioprocessing
    • Cancer
    • Drug Discovery
    • Genome Editing
    • Infectious Diseases
    • OMICs
    • Translational Medicine
  • Magazine
    • Browse Issues
    • Subscribe
  • Multimedia
    • Summits
    • Webinars
    • GEN Live
    • Learning Labs
    • Podcasts
  • Resources
    • eBooks/Perspectives
    • Tutorials
    • Peer-Reviewed Journals
      • GEN Biotechnology
      • Re:Gen Open
    • New Products
    • Conference Calendar
  • Subscribe
    • Get GEN Magazine
    • Get GEN eNewsletters
Home 2023

Apellis

As Biopharma Giants Reshape the Field, Cognition Therapeutics Sees a Place for Its Alzheimer’s Drug
Drug Discovery

As Biopharma Giants Reshape the Field, Cognition Therapeutics Sees a Place for Its Alzheimer’s Drug

StockWatch: French Raid Shows Little Effect on Nvidia Price
Artificial Intelligence

StockWatch: French Raid Shows Little Effect on Nvidia Price

StockWatch: Short Seller Briefly Dents Apellis Shares
GEN Edge

StockWatch: Short Seller Briefly Dents Apellis Shares

Apellis Axing 25% of Staff, Shifting Resources to GA Drug
Drug Discovery

Apellis Axing 25% of Staff, Shifting Resources to GA Drug

StockWatch: Apellis Shares Nosedive 73% on Safety Concerns
Drug Discovery

StockWatch: Apellis Shares Nosedive 73% on Safety Concerns

StockWatch: Apellis Wows Analysts with First FDA Approval for GA Therapy
Cancer

StockWatch: Apellis Wows Analysts with First FDA Approval for GA Therapy

Complementary Challenge: Apellis Throws Down the Gauntlet
Drug Discovery

Complementary Challenge: Apellis Throws Down the Gauntlet

Apellis Pharmaceuticals – APL-9
News

Apellis Pharmaceuticals – APL-9

Apellis to Acquire Potentia, Four Years After Spinout
News

Apellis to Acquire Potentia, Four Years After Spinout

Read the Digital Edition

August 2023 cover

Explore

  • About GEN
  • Contact GEN
  • GEN Staff
  • Editorial Guidelines
  • Reprints and Permissions
  • Scientific Advisory Board

Advertise

  • Media Kit and Planning Calendar
  • Advertising Terms and Conditions

Resources

  • Get the GEN Magazine
  • Get the GEN Email Newsletter
  • Inside Precision Medicine
  • Privacy Policy
Copyright © 2023 Genetic Engineering & Biotechnology News. All Rights Reserved.
Scroll Up